Replies to post #191 on Equity Field Notes from temporal sources

[DanWebzster]

JNCE is an immuno-oncology firm with a Ph2 therapy that has not performed up to market expectations.

Its T-effector technology involves: 1) creating an antigenic response 2) attaching to natural killer (NK) cells and directing them to kill regulator cells that block T-cells from getting to the tumor.

This MOA shows efficacy in cancer sub-types with high NK populations and seems to reverse anti-PD1 inhibitor failures.

CELG has an option on the entire pipeline. This technology may complement CELG's new immuno-oncology focus.

Although JNCE has a cash runway of ~2 years, it is doubtful that their runway would make it all the way to commercialization of their lead compound